Bumgardner G L, Gao D, Li J, Baskin J H, Heininger M, Orosz C G
The Ohio State University College of Medicine, Department of Surgery, the Comprehensive Cancer Cente, Columbus 43210-1250, USA.
Transplantation. 2000 Dec 27;70(12):1771-80. doi: 10.1097/00007890-200012270-00017.
The purpose of the current study was to investigate the capacity of CD4+, CD8+, or non-T cells to independently initiate acute rejection of allogeneic hepatocytes using reconstituted SCID, CD4 or CD8 knockout (KO) recipient mice.
Allogeneic hepatocytes (FVB/N, H-2q) were transplanted into C57BL/6.SCID (H-2b), CD4 KO (H-2b), CD8 KO (H-2b), or beige/beige (H-2b) mice. SCID mice with functioning hepatocellular allografts subsequently received purified non-T cells (NTC), CD4+, or CD8+ splenocytes. Some mice were treated with anti-CD4, anti-CD8, and/or anti-nkl.1 mAb. Recipient mice were also assessed for donor-reactive delayed-type hypersensitivity (DTH) responses and donor-reactive alloantibody production.
Median hepatocellular allograft survival time (MST) was 28 days in CD4+ reconstituted SCID mice and 14 days in CD8+ reconstituted SCID mice. SCID hosts reconstituted with NTC demonstrated indefinite hepatocellular allograft survival (>120 days). MST was 10 days in untreated beige/beige (NK cell deficient) mice. MST was 14 days in untreated, 35 days in anti-CD4 mAb treated, and 10 days in anti-nkl.1 mAb treated CD8 KO mice. MST was 10 days in untreated, 35 days in anti-CD8 mAb treated, and 7 days in anti-nk1.1 mAb treated CD4 KO mice. Donor-reactive DTH responses were not detected in reconstituted SCID mice, were minimal in CD4 KO mice, and were prominent in CD8 KO mice after rejection of allogeneic hepatocytes. Similarly, donor-reactive alloantibody, was not detected in CD4 KO hosts, but was readily detected in CD8 KO hosts.
These studies show that both CD4+ and CD8+ T cells (but not host NTC) can independently initiate the rejection of allogeneic hepatocytes. While hepatocyte rejection by isolated CD4+ T cells is not surprising, rejection by CD8+ T cells (in the absence of CD4+ T cells) was unusual, and may explain the failure of "standard" immunosuppressive regimens to suppress acute rejection of allogeneic hepatocytes, as noted in prior studies. Furthermore, NK cells do not appear to be required for either CD4+ T cell or CD8+ T cell initiated hepatocyte rejection.
本研究的目的是利用重组的重症联合免疫缺陷(SCID)、CD4或CD8基因敲除(KO)受体小鼠,研究CD4⁺、CD8⁺或非T细胞独立引发同种异体肝细胞急性排斥反应的能力。
将同种异体肝细胞(FVB/N,H-2q)移植到C57BL/6.SCID(H-2b)、CD4基因敲除(H-2b)、CD8基因敲除(H-2b)或米色/米色(H-2b)小鼠体内。具有功能的肝细胞同种异体移植的SCID小鼠随后接受纯化的非T细胞(NTC)、CD4⁺或CD8⁺脾细胞。一些小鼠用抗CD4、抗CD8和/或抗nkl.1单克隆抗体治疗。还评估了受体小鼠的供体反应性迟发型超敏反应(DTH)和供体反应性同种异体抗体的产生。
在CD4⁺重组的SCID小鼠中,肝细胞同种异体移植的中位存活时间(MST)为28天,在CD8⁺重组的SCID小鼠中为14天。用NTC重组的SCID宿主显示肝细胞同种异体移植存活时间不确定(>120天)。未治疗的米色/米色(NK细胞缺陷)小鼠的MST为10天。未治疗的CD8基因敲除小鼠的MST为14天,抗CD4单克隆抗体治疗的为35天,抗nkl.1单克隆抗体治疗的为10天。未治疗的CD4基因敲除小鼠的MST为10天,抗CD8单克隆抗体治疗的为35天,抗nk1.1单克隆抗体治疗的为7天。在重组的SCID小鼠中未检测到供体反应性DTH反应,在CD4基因敲除小鼠中最小,在同种异体肝细胞排斥后,在CD8基因敲除小鼠中很明显。同样,在CD4基因敲除宿主中未检测到供体反应性同种异体抗体,但在CD8基因敲除宿主中很容易检测到。
这些研究表明,CD4⁺和CD8⁺T细胞(但不是宿主NTC)都可以独立引发同种异体肝细胞的排斥反应。虽然分离的CD4⁺T细胞对肝细胞的排斥并不奇怪,但CD8⁺T细胞(在没有CD4⁺T细胞的情况下)的排斥是不寻常的,这可能解释了先前研究中提到的“标准”免疫抑制方案未能抑制同种异体肝细胞急性排斥反应的原因。此外,NK细胞似乎不是CD4⁺T细胞或CD8⁺T细胞引发肝细胞排斥反应所必需的。